Filing Flows

Filing Flows › Arbutus Biopharma (ABUS) › Who owns the stock

Who owns Arbutus Biopharma (ABUS) stock

174 funds reported Arbutus Biopharma (ABUS) shares in their latest 13F filings, worth $2.9B in all. The largest holder is Corbin Capital Partners, L.P. ($2.2B). Last quarter 85 funds added to their stakes and 59 cut them.

Largest holders of ABUS (13F)Largest holders of ABUS (13F)Corbin Capital Partners, L.P.$2.2BMorgan Stanley$85.0MWhitefort Capital Management, LP$75.8MBlackRock$66.1MVanguard Group$44.5MTwo Seas Capital LP$38.9MState Street$37.8MRubric Capital Management LP$36.2MVanguard Capital Management LLC$33.7MGeode Capital Management, LLC$19.8M

Largest holders (13F)

FundSharesValueChangeQuarter
Corbin Capital Partners, L.P.682,487$2.2Bdecrease2024-12-31
Morgan Stanley17,698,305$85.0Mdecrease2026-06-30
Whitefort Capital Management, LP15,794,261$75.8Mincrease2026-06-30
BlackRock13,766,071$66.1Mincrease2026-06-30
Vanguard Group9,242,437$44.5Mincrease2025-12-31
Two Seas Capital LP8,143,994$38.9Mdecrease2026-09-30
State Street7,869,179$37.8Mincrease2026-06-30
Rubric Capital Management LP7,532,937$36.2Mincrease2026-06-30
Vanguard Capital Management LLC7,010,679$33.7Mincrease2026-06-30
Geode Capital Management, LLC4,117,691$19.8Mincrease2026-06-30
Goldman Sachs Group3,506,802$16.8Mincrease2026-06-30
Bank of America2,646,197$12.7Mincrease2026-06-30
Barclays2,548,572$12.2Mdecrease2026-09-30
BlackBarn Capital Partners LP2,500,000$12.0Munchanged2026-06-30
Legal & General Group2,466,127$11.8Mincrease2026-06-30

Arbutus Biopharma's latest quarter

Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most ABUS stock?

By the latest 13F filings: Corbin Capital Partners, L.P. ($2.2B); Morgan Stanley ($85.0M); Whitefort Capital Management, LP ($75.8M); BlackRock ($66.1M); Vanguard Group ($44.5M).

What is the short interest in ABUS?

24,566,591 shares were sold short at the 2026-10-15 settlement, -27.86% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.